IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection

J Immunol. 1995 Sep 1;155(5):2515-24.

Abstract

IL-12, a cytokine produced by macrophages and B cells, has recently been found to exert pleiotropic effects on the immune system. When BALB/c mice, a strain highly susceptible to virulent Mycobacterium tuberculosis infection, were given IL-12 at the initiation of infection with M. tuberculosis, their mean survival time doubled from 58 to 112 days. IL-12-treated mice had diminished bacterial burdens, whereas treatment with exogenous IFN-gamma had no effect on survival or bacterial burden. IL-12 treatment also delayed lung pathology in BALB/c mice. In contrast with the findings in the BALB/c model, IL-12 did not increase survival of M. tuberculosis-infected gko mice, transgenic mice in which the IFN-gamma gene has been disrupted, indicating that IL-12 does not induce protection against tuberculosis in mice in the absence of IFN-gamma.

MeSH terms

  • Animals
  • BCG Vaccine / therapeutic use
  • Female
  • Granuloma / pathology
  • Immunity, Innate
  • Interferon-gamma / pharmacology
  • Interferon-gamma / therapeutic use
  • Interleukin-12 / pharmacology*
  • Lymphokines / biosynthesis
  • Lymphokines / genetics
  • Major Histocompatibility Complex / physiology
  • Mice
  • Mice, Inbred BALB C / immunology*
  • Mice, Inbred C57BL
  • Mice, Inbred Strains
  • Mice, Mutant Strains
  • Mycobacterium tuberculosis / drug effects
  • Tuberculosis / immunology*
  • Tuberculosis / prevention & control

Substances

  • BCG Vaccine
  • Lymphokines
  • Interleukin-12
  • Interferon-gamma